Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- Council OKs Application Based on Info in Public Domain for Taxol Once Weekly for 3 Weeks for Gastric Cancer
January 26, 2015
- PMDA Evaluating Apixaban for Risk of Interstitial Pneumonia
January 26, 2015
- Government Launches Genomic Medicine Panel
January 23, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
- NIBIO Completes Development of Prototype Adjuvant Database
January 22, 2015
- PAFSC’s Second Committee on Drugs Recommends Approval for Eisai’s Lenvatinib
January 22, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- Health Ministry Reveals Guidelines on Research Misconduct
January 20, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
- Consumer Affairs Agency to Begin Study on Child-Resistant PTP Sheets
January 20, 2015
- PAFSC 1st Committee to Discuss Takeda’s Once-Weekly DPP-4 Inhibitor on Jan. 30
January 20, 2015
- NIBIO to Launch Project to Collate Compound Libraries, Academic Seeds
January 19, 2015
- AMED Chief-to-Be Vows to Overhaul Siloed Research Grants
January 19, 2015
- PMDA Head Expresses Full Support for AMED
January 19, 2015
- 112.8 Billion Yen Allotted to Intractable Disease Measures
January 19, 2015
- 65 Institutions to Treat Post-HPV Vaccine Adverse Reactions
January 16, 2015
- MHLW to Reorganize Health Service Bureau in FY2015
January 16, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…